NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...
Physician-patient communication and shared decision-making approaches in myeloproliferative neoplasm care. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...
Atrial fibrillation developed in 6.6% of JAK2V617F-positive MPN patients, increasing stroke and mortality risks significantly. Elevated interleukin-1β and TET2 mutations were identified as independent ...
BOZEMAN, MONTANA, USA, February 1, 2024 /EINPresswire.com/ -- Alercell, Inc., an innovative leader in molecular diagnostics, has recently unveiled its latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results